Via practica 2/2020

New trends in metastatic hormone-sensitive prostate cancer treatment

Over the past 5 years, the treatment of metastatic hormone-sensitive prostate cancer has undergone substantial changes. The original treatment with androgen deprivation therapy (ADT) alone has been replaced by a combination treatment of ADT with the chemotherapeutic docetaxel or a combination of ADT with androgen signaling inhibitors abiraterone, enzalutamide and apalutamide. All combination therapies significantly prolong overall survival compared to ADT alone while maintaining good quality of life. New treatment options for patients with mHSPC include local prostate radiotherapy, which also prolongs the overall survival of the selective group of patients. Although currently under our conditions we have access only to the treatment of ADT in combination with docetaxel, we can also expect access to less toxic combinations of ADT with androgen signaling pathway inhibitors which should become the standard in the treatment of patients with mHSPC.

Keywords: metastatic hormone-sensitive prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, radiotherapy